Research programme: eye disorder therapies - AlphaRxAlternative Names: AL 0155; Binoxan; LT 0155
Latest Information Update: 22 Sep 2011
At a glance
- Originator AlphaRx
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections; Eye disorders; Inflammation
Most Recent Events
- 05 Jul 2011 Discontinued - Preclinical for Inflammation in Canada (Ophthalmic)
- 05 Jul 2011 Discontinued - Preclinical for Eye disorders in Canada (Ophthalmic)
- 05 Jul 2011 Discontinued - Preclinical for Bacterial infections in Canada (Ophthalmic)